↓ Skip to main content

Five or more years of adjuvant endocrine therapy in breast cancer: a meta-analysis of published randomised trials

Overview of attention for article published in Breast Cancer Research and Treatment, July 2013
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (78th percentile)
  • Good Attention Score compared to outputs of the same age and source (77th percentile)

Mentioned by

policy
1 policy source
twitter
5 tweeters

Citations

dimensions_citation
25 Dimensions

Readers on

mendeley
31 Mendeley
Title
Five or more years of adjuvant endocrine therapy in breast cancer: a meta-analysis of published randomised trials
Published in
Breast Cancer Research and Treatment, July 2013
DOI 10.1007/s10549-013-2629-4
Pubmed ID
Authors

Fausto Petrelli, Andrea Coinu, Mary Cabiddu, Mara Ghilardi, Veronica Lonati, Sandro Barni

Abstract

Five years of adjuvant hormonal therapy is the standard of care in early breast cancer (BC) expressing oestrogen receptors (ER+). Prolonged duration of adjuvant endocrine therapy is implemented to prevent recurrence and death; in particular, its carryover effect may prevent very late events. This meta-analysis compares the efficacy of 5 years of hormonal therapy alone with that of additional years of hormonal therapy, in patients with early BC. Randomised trials comparing 5 years versus more than 5 years of hormonal therapy in BC were identified by electronic searches of PubMed, EMBASE, ISI Web of Science and the Cochrane Central Register of Controlled Trials. Meta-analysis was performed using the fixed- or random-effects models. The primary endpoints were overall survival (OS), BC-specific survival (BCSS) and relapse-free survival (RFS) reported as odds ratios (ORs) and 95 % confidence interval (CI). Eight trials, including 29,138 patients, were identified. Overall, in ER+ BCs, extended endocrine therapy beyond 5 years of tamoxifen significantly improved OS (OR, 0.89; 95 % CI 0.80-0.99; P = 0.03), BCSS (OR, 0.78; 95 % CI 0.69-0.9; P = 0.0003) and RFS (OR 0.72; 95 % CI 0.56-0.92; P = 0.01) compared with 5 years of hormonal therapy alone. Loco-regional and distant relapses were reduced by 36 and 13 %, respectively. Compared with 5 years of tamoxifen, additional adjuvant endocrine therapy reduced risk of death and relapse of ER+ BC by ~10 and 30 %, respectively. This strategy should be considered in patients free of disease after 5 years of hormonal therapy.

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 31 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Japan 1 3%
Unknown 30 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 7 23%
Other 5 16%
Student > Ph. D. Student 4 13%
Student > Bachelor 3 10%
Unspecified 3 10%
Other 9 29%
Readers by discipline Count As %
Medicine and Dentistry 16 52%
Unspecified 4 13%
Psychology 3 10%
Nursing and Health Professions 2 6%
Computer Science 1 3%
Other 5 16%

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 July 2018.
All research outputs
#3,013,139
of 13,237,907 outputs
Outputs from Breast Cancer Research and Treatment
#728
of 3,239 outputs
Outputs of similar age
#32,725
of 154,959 outputs
Outputs of similar age from Breast Cancer Research and Treatment
#8
of 36 outputs
Altmetric has tracked 13,237,907 research outputs across all sources so far. Compared to these this one has done well and is in the 77th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,239 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.4. This one has done well, scoring higher than 77% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 154,959 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 78% of its contemporaries.
We're also able to compare this research output to 36 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 77% of its contemporaries.